Ables Iannone Moore & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Ables Iannone Moore & Associates’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-225	Closed	-$11.5K	–	100
2023 Q4	$11.5K	Buy	+225	New	+$11.8K	0.01%	176

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ables Iannone Moore & Associates's BMY Position: Q1 2024 in Review

Ables Iannone Moore & Associates sold out of Bristol-Myers Squibb (BMY) in Q1 2024, closing a stake of 225 shares — an estimated $11.5K sold.

Ables Iannone Moore & Associates first reported a position in BMY in Q4 2023 and held it in 1 quarter. The position peaked at $11.5K in Q4 2023. 2,339 funds tracked by Wall St. Rank hold BMY as of Q1 2024.

Ables Iannone Moore & Associates reported no remaining Bristol-Myers Squibb position as of Q1 2024 after selling out during the quarter.
Ables Iannone Moore & Associates sold 225 Bristol-Myers Squibb shares in Q1 2024, an estimated $11.5K.
Ables Iannone Moore & Associates first reported a position in Bristol-Myers Squibb in Q4 2023 and held it in 1 quarter.
Ables Iannone Moore & Associates's Bristol-Myers Squibb position peaked at $11.5K in Q4 2023.
2,339 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2024.

Based on Ables Iannone Moore & Associates's 13F filing for Q1 2024, filed 30 Apr 2024.